Medicare Part D Now Covers GLP-1s for Weight Loss Under New CMS Policy
Insurance coverage for GLP-1 medications used for weight loss has changed for approximately 56 million Americans. The policy shift affects Medicare Part D beneficiaries and potentially other federal health programs. The coverage expansion comes as GLP-1 drugs like Ozempic and Wegovy gain widespread use for obesity treatment. Medicare previously covered these medications only for diabetes, not weight management alone, making this a significant benefit expansion with major cost implications for plans and enrollees.
Medicaid managed care plans may face increased utilization and pharmacy costs if states adopt similar coverage policies for GLP-1s beyond diabetes indications, requiring formulary reviews and prior authorization strategy updates.
Pharmacy · Managed Care
You might also like